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Background: The antipoxviral activities and phosphor‑
ylation of N‑methanocarbathymidine ([N]-MCT) and
four 5‑halo-2′-deoxyuridines, namely 5‑fluoro- (FdU),
5‑chloro- (CldU), 5‑bromo- (BrdU), and 5‑iodo- (IdU)
derivatives, were explored.
Methods: Antiviral activities and nucleoside metabolism
were determined in C127I mouse, LLC-MK2 monkey,
and A549 human cells infected with thymidine-kinasecontaining and -deficient (TK+ and TK‑) vaccinia (WR
strain) viruses.
Results: The antiviral potencies of CldU, BrdU and IdU
were increased 16–26‑fold in LLC-MK2 cells infected with
TK+ compared with TK‑ virus infections, but enhancement
of activity was much less in the other cell lines. (N)-MCT
was nearly equally active against TK+ and TK‑ viruses in
the three cell lines. Antiviral activity of FdU was asso‑
ciated with cytotoxicity. Uninfected and infected cells
metabolized compounds to mono-, di‑ and triphosphates.

The thymidine, BrdU and IdU triphosphate levels were
higher in C127I and LLC-MK2 cells infected with TK+
than with TK‑ virus. (N)-MCT monophosphate levels were
much higher in TK+ virus-infected cells, but without cor‑
responding increases in (N)-MCT triphosphate. Further‑
more, TK+ virus infections did not appreciably alter (N)MCT triphosphate levels in other mouse (L929), monkey
(MA-104 and Vero) and human cell lines (A549). Antiviral
potency of the compounds was greater in C127I than in
LLC-MK2 cells, yet lower intracellular triphosphate levels
were found in C127I cells.
Conclusion: We conclude that viral TK plays an important
role in increasing the antiviral potencies of these com‑
pounds in some cell lines, but minimally in others. These
findings may have implications in treating infected ani‑
mals with compounds that are dependent upon poxvirus
TK for their activation, because viral TK activity may vary
greatly due to cell type.

Introduction
It has long been recognized that herpes simplex virus
thymidine kinase (TK) is able to phosphorylate certain
nucleoside analogues to their monophosphate forms in
infected cells, whereas host cells do this poorly [1,2].
This effect has led to the identification of selective anti‑
viral compounds, some of which have been developed
as drugs, including idoxuridine, acyclovir, ganciclovir
and penciclovir [3]. The herpes simplex virus pos‑
sesses a type I TK that has a broader substrate specifi‑
city than the host cell type II TK and orthopoxvirus
type II TK [4,5]. Because of the narrow substrate spe‑
cificity of poxvirus TK, there have been few discoveries
of compounds that are selectively phosphorylated by
poxvirus TK. Prichard and colleagues [6,7] presented
evidence that the antiviral potencies of 5‑bromo-2′deoxyuridine (BrdU), 5‑iodo-2′-deoxyuridine (IdU) and
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N‑methanocarbathymidine [(N)-MCT] were greater
against TK-containing (TK+) cowpox virus than against
TK‑deficient (TK-) cowpox virus. This suggested that
the compounds were activated by cowpox virus TK and
gave an indication that the poxvirus TK differs slightly
from host cell TK in substrate specificity. This feature
of the virus may be exploited to identify selective new
poxvirus inhibitors. Indeed, Prichard and colleagues [8]
later reported a series of 2′‑deoxyuridine derivatives
whose antiviral activity was highly dependent upon
poxvirus TK.
The antipoxvirus activities of certain compounds
may be dependent upon the cell line in which the assay
was conducted. For example, we found that BrdU was
more potent against TK+ than TK‑ vaccinia virus, but
this effect was only seen in Vero monkey cells and A549
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human cells and not in C127I mouse cells [9]. The
antiviral potency of (N)-MCT in each of these three
cell lines differed markedly, but the minimal inhibi‑
tory concentrations against TK+ and TK‑ viruses in a
particular cell line were nearly the same [9].
Differences in antiviral potency of nucleoside ana‑
logues associated with the cell line used for assay are
often due to differences in intracellular phosphoryla‑
tion of such compounds. For example, ribavirin and
cidofovir are more potent against poxviruses in mouse
cells than in monkey cells, a result of greater phospho‑
rylation in mouse cells ([10] and unpublished observa‑
tions). In the present study, we endeavoured to better
understand how poxvirus TK contributes to antivi‑
ral potency in cell culture, and whether differences in
antiviral potency in cell lines were related to differ‑
ent degrees of intracellular phosphorylation. We used
commercially available radioactive BrdU and IdU and
custom-synthesized (N)-MCT as probes of nucleoside
metabolism, working on the premise that the nucle‑
oside triphosphate form is primarily the active antiviral
moiety of these substances [11–13].

Methods
Compounds
Thymidine, 5‑fluoro-2′-deoxuridine (FdU), 5‑chloro2′-deoxyuridine (CldU), BrdU and IdU were pur‑
chased from Sigma (St. Louis, MO, USA). (N)-MCT
or (north)-methanocarbathymidine [13,14], also
referred to as N‑methanocarbathymine or (north)methanocarbathymine [15], was provided through
the Antiviral Substances Program of the National
Institute of Allergy and Infectious Diseases, National
Institutes of Health (Bethesda, MD, USA). The syn‑
thesis of this compound has been published elsewhere
[16]. [Methyl-3H]thymidine (24.6 Ci/mmol), [6‑3H]
BrdU (24.5 Ci/mmol), [6‑3H]IdU (16.2 Ci/mmol) and
[methyl-3H](N)-MCT (4.7 Ci/mmol) were purchased
from Moravek Biochemicals (Brea, CA, USA). Nonradioactive compounds were combined with their
respective radioactive forms to obtain 5 and 100 µM
concentrations used for phosphorylation experiments.

Viruses and cells
Three forms of vaccinia virus (WR strain) were
obtained from the American Type Culture Collection
(ATCC, Manassas, VA, USA). They were wild-type
(WT), S‑variant (S‑Var) and S‑Var vTK-79 strains. The
vTK-79 strain is TK-, as indicated in ATCC literature,
that was derived from the S‑Var virus by passage in
the presence of 5‑bromo-2′-deoxyuridine, whereas the
other two strains are TK+. The WT virus produces large
plaques and the two forms of the S‑Var virus produce
small plaques in cell culture. High titre virus pools were
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prepared in African green monkey kidney (MA-104)
cells (BioWhittaker, Walkersville, MD, USA). Other cell
lines used for the research included mouse mammary
tumour (C172I), mouse connective tissue (NCTC clone
929 or L929), African green monkey kidney (Vero),
rhesus monkey kidney (LLC-MK2) and human lung car‑
cinoma (A549) cells, all obtained from ATCC. Cell cul‑
ture medium for propagating C127I, L929, LLC-MK2,
and MA‑104 cells was MEM with 10% fetal bovine
serum (FBS) and 0.18% sodium bicarbonate. MEM
with 5% FBS and 0.18% bicarbonate was used to grow
Vero cells. Ham’s F12K medium containing 10% FBS,
2 mM glutamine and 0.15% bicarbonate was used
for A549 cells. For antiviral assays, the appropriate
medium for each type of cell culture contained 50 µg/ml
of gentamicin and the FBS concentration was reduced
to 2%. For antiviral and phosphorylation assays, the
appropriate medium for each type of cell culture con‑
tained 2% FBS and 50 µg/ml of gentamicin. Cell pro‑
liferation assays used cell culture medium containing
full-strength FBS (as indicated above) and gentamicin.

Plaque reduction, cytotoxicity and virus yield
reduction assays
Determinations of the antiviral activities of the four
5‑halo-2′-deoxyuridine compounds were made in
12‑well microplates of confluent C127I, LLC-MK2
and A549 cells by plaque reduction assay, as previ‑
ously described, using multiple half-log10 dilutions of
test compound [9]. Cytotoxicity assays were performed
using semi-confluent cell monolayers in 24‑well micro‑
plates. Approximately 2×104 cells were seeded and
allowed to attach overnight followed by treatment
with compounds for 3 days. Determinations of per‑
cent inhibition of cell replication were made by neutral
red staining [9]. (N)-MCT has already been shown to
inhibit vaccinia virus strains by plaque reduction assay
and to be non-cytotoxic at 1,000 µM to replicating cells
[9]. To confirm the observations of antiviral activity of
(N)-MCT, virus yield reduction assays were performed
in C127I, LLC-MK2 and A549 cells. Approximately
400 plaque-forming units (PFU) of virus were used to
infect each well of 12‑well microplates. After 1 h of
virus adsorption, (N)-MCT was added at varying halflog10 dilutions. Virus titration plates were run in paral‑
lel to get an accurate count of input virus. At 3 days, the
virus-containing plates were frozen at -80°C. The fro‑
zen plates were later thawed, the cells and supernate were
sonicated for 45 s each and the entire yield of virus (intra‑
cellular and extracellular) from each well was titrated
in 12‑well plates of Vero cells, followed 3 days later by
fixing, staining (0.2% crystal violet in 10% buffered
formalin for 15 min) and counting of the plaques. Final
results were converted to log10 PFU/ml of virus that were
normalized to 400 PFU of input virus per cell culture.
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Because the C127I cells required about 1,000-fold more
S‑Var and TK‑ viruses to infect with the same relative
PFU as the other cell lines, we were concerned that this
input virus might persist and be detected later during
virus titrations. Subsequently, we discovered by titrat‑
ing virus from cells after only a 6 h incubation period
that we could recover this virus by Vero cell titration,
whereas WT virus could not be detected (that is, it had
uncoated). In virus yield reduction assays, the results
showed about 103 PFU of S‑Var and TK‑ viruses recov‑
ered from C127I cells treated with all concentrations
from 10 to 1,000 µM. We believe this to be the input
virus that could not initially infect the cells rather than
progeny virus. Thus, the graphs represent plots where
103 PFU was subtracted from the titres to eliminate this
background virus.

Preparation of cell extracts for nucleotide analysis
Cells were infected with virus at a multiplicity of
infection (MOI) of approximately 5 PFU per cell. After
1 h of virus adsorption, infected and uninfected cells
in T‑25 flasks were exposed to 3H‑(N)-MCT (10 µCi/
ml), 3H‑BrdU (5 µCi/ml), 3H‑IdU (5 µCi/ml) or 3H‑thy‑
midine (5 µCi/ml) for 12 h. Because of the high MOI
used, degradation of the cells and decreases in radio‑
activity were evident at later time points. After incu‑
bation, the medium was removed and the cells in the
flasks were treated with 0.5 ml of 3.5% perchloric acid.
After 5 min at 4°C, the acid extracts were neutralized
with 0.25 ml of 1 N KOH/1 M imidazole. This resulted
in the formation of a precipitate that was later pelleted
by centrifugation. The resulting supernates were frozen
at -80°C until analysed. For each experiment, untreated
flasks of cells were trypsinized prior to the start of each
infection and the cells were counted using a haemacytom‑
eter in order to calculate viral MOI, which was necessary
for determining picomoles of nucleoside mono-, di‑ and
triphosphates per 106 cells.

Nucleotide analysis
Separation of 3H‑nucleosides from their phosphorylated
metabolites was done by a modification of a high pressure
liquid chromatography (HPLC) method previously
described [17]. Briefly, 400 µl samples were analysed
using an HPLC system (Varian Chromatography
Systems, Woburn, MA, USA) fitted with a Whatman
(Clifton, NJ, USA) 10 mm × 25 cm SAX column with
a linear gradient of 10 mM (pH 7.0)–1 M ammonium
phosphate buffer (pH 3.5) and a 1 ml/min flow rate. The
10 mM buffer was run for the first 5 min, followed by
the gradient from 5 to 25 min. Then, the 1 M buffer was
run for an additional 15 min prior to re‑equilibration
at the low salt concentration in preparation for the
next analysis. Using the 10 mM buffer at pH 7.0
and allowing it to flow for 5 min prior to starting the
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gradient were necessary for adequately separating the
monophosphate from the parent compound (whose
large peak of radioactivity eluted from the column
with a long tail). The gradient conditions were worked
out using non-radioactive thymidine nucleotides
(purchased from Sigma). Determinations of the amount
of radioactive metabolites of compounds were made
by collecting 1 ml fractions in vials, followed by liquid
scintillation spectroscopy. Retention times of the parent
compound and the mono-, di‑ and triphosphates of
(N)-MCT, BrdU and IdU were approximately those of
thymidine metabolites.
Because of the very low level of phosphorylation
of (N)-MCT in cells, an adjustment had to be made
for background counts resulting from the nucleoside
itself eluting throughout the entire gradient. In order
to quantify the background, so that it could be sub‑
tracted out, an injection of approximately the same
amount of radioactivity of the nucleoside as was
detected in the cell culture-derived samples was made,
and vials were collected and counted for radioactivity.
Small amounts of radioactivity were found in every
fraction, although the vast majority of counts eluted
between fractions 4 and 12. A ratio of radioactivity
in the sample peak for fractions 4–12 to the corre‑
sponding background peak was made. Then the total
background counts found in fractions correspond‑
ing to where the mono-, di‑ and triphosphate peaks
were found for the test samples were multiplied by
this ratio and the resulting value was subtracted from
the total counts in the peaks. By this method, a more
accurate estimate of phosphate forms of (N)-MCT in the
cells could be made. Values were reported as picomoles
of radioactivity per 106 cells.

Results
Antiviral activities and cytotoxicities of nucleosides
in cell culture
Plaque reduction assays were performed to determine
the activities of compounds in cells infected with TK+
and TK‑ vaccinia viruses (Table 1). FdU was highly
potent against the three viruses in C127I and LLC-MK2
cells, with inhibition seen at <0.1 µM. Accompanying
the antiviral activity of FdU was cytotoxic, resulting
in low selectivity index values of 2.2–6.7. The activ‑
ity ratio of TK‑ to TK+ virus indicated minimal potency
differences or a lack of viral TK involvement in the
antiviral effect of the compound in those cells. FdU did
not exhibit antiviral activity in A549 cells and was not
toxic to those cells.
CldU, BrdU and IdU were similarly potent against
the vaccinia virus infections (Table 1). Antiviral
potencies of the three compounds in C127I cells
ranged from 0.5 to 1.6 µM, and were not appreciably
17
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affected by the TK status of the virus. However,
there were large differences (16–26‑fold) in antiviral
potency of the compounds in LLC-MK2 cells infected
with TK+ viruses compared with TK‑ virus infection.
In A549 cells, there was a moderate enhancement of
activity in the TK+ cells ranging from 3.1- to 4.6-fold.
In general, these three compounds were most potent

against TK+ virus infections in C127I cells, followed
by LLC-MK2 and A549 cells.
(N)-MCT was much more potent in C127I cells
(50% effective concentrations of 0.5–0.9 µM) than
in LLC-MK2 (183–273 µM) or A549 (17–29 µM)
cells (Table 1). The TK‑ virus infection was inhibited
by approximately the same concentrations as those

Table 1. Antiviral activities of 5-halogenated 2-deoxyuridines and (N)-MCT in various cell lines against vaccinia (WR strain)
TK+ and TK- viruses
						
Compound
Cell line
Virus
EC50*, µM
IC50†, µM
SI‡
FdU
C127I§
		
		
LLC-MK2¶
		
		
A549#
		
		
CldU
C127I§
		
		
LLC-MK2¶
		
		
A549#
		
		
BrdU
C127I§
		
		
LLC-MK2¶
		
		
A549#
		
		
IdU
C127I§
		
		
LLC-MK2¶
		
		
A549#
		
		
(N)-MCT
C127I§**
		
		
LLC-MK2¶
		
		
A549#
		
		

WT
S-Var
TKWT
S-Var
TKWT
S-Var
TKWT
S-Var
TKWT
S-Var
TKWT
S-Var
TKWT
S-Var
TKWT
S-Var
TKWT
S-Var
TKWT
S-Var
TKWT
S-Var
TKWT
S-Var
TKWT
S-Var
TKWT
S-Var
TKWT
S-Var
TK-

0.009 ±0.004
0.003 ±0.002
0.004 ±0.002
0.034 ±0.014
0.015 ±0.005
0.034 ±0.006
>1,000
>1,000
>1,000
1.6 ±0.3
0.5 ±0.2
1.2 ±0.5
1.9 ±0.7
4.1 ±1.2
85 ±14
16 ±2.0
13 ±6.0
42 ±16
1.2 ±0.5
0.8 ±0.4
0.8 ±0.5
0.9 ±0.2
3.5 ±1.3
55 ±13
8.1 ±3.4
7.6 ±4.4
35 ±13
1.5 ±0.2
0.6 ±0.5
1.0 ±0.5
2.7 ±1.0
3.5 ±1.1
90 ±28
14 ±1.5
13 ±2.2
40 ±16
0.9 ±0.3
0.5 ±0.1
0.6 ±0.1
253 ±85
183 ±59
273 ±120
29 ±3.5
17 ±4.9
22 ±5.8

0.020 ±0.019
0.020 ±0.019
0.020 ±0.019
0.083 ±0.021
0.083 ±0.021
0.083 ±0.021
>1,000
>1,000
>1,000
>1,000
>1,000
>1,000
>1,000
>1,000
>1,000
>1,000
>1,000
>1,000
>1,000
>1,000
>1,000
>1,000
>1,000
>1,000
>1,000
>1,000
>1,000
>1,000
>1,000
>1,000
>1,000
>1,000
>1,000
>1,000
>1,000
>1,000
>1,000
>1,000
>1,000
>1,000
>1,000
>1,000
>1,000
>1,000
>1,000

2.2
6.7
5.0
2.4
5.5
2.4
–
–
–
>625
>2,000
>833
>526
>244
>12
>63
>77
>24
>833
>1,250
>1,250
>1,110
>286
>18
>123
>132
>29
>667
>1,667
>1,000
>370
>286
>11
>71
>77
>25
>1,110
>2,000
>1,667
>4.0
>5.5
>3.7
>34
>59
>45

Activity ratio
(TK-/S-Var)

1.3

2.3

–

2.4

21

3.2

1.0

16

4.6

1.7

26

3.1

0.8

1.5

1.3

The wild-type (WT) and S-variant (S-Var) viruses contain thymidine kinase (TK+). The TK-deficient (TK-) virus was derived from the S-Var virus. *Fifty percent effective
(virus-inhibitory) concentration ±sd (three independent assays) determined by plaque reduction assay. †Fifty percent cell-inhibitory concentration ±sd (three independent
assays) of actively dividing uninfected cells. ‡Selectivity index (IC50 divided by EC50). Cells originated from §mouse, ¶monkey and #human. **EC50 values and activity ratios for
(N)-MCT in this cell line were previously reported [9]. BrdU, 5‑bromo-2′-deoxyuridine; CldU, 5‑chloro-2′-deoxyuridine; FdU, 5‑fluoro-2′-deoxuridine; IdU, 5‑iodo-2′deoxyuridine; (N)-MCT, N‑methanocarbathymidine.
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Figure 1. Effect of (N)-MCT on virus yields from cells
infected with TK+ (wild-type and S-Var) and S-Var TKstrains of vaccinia virus
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Infected and uninfected cells were treated with
3
H‑compounds and incubated for 12 h, followed by
HPLC analysis of intracellular nucleotides (Figure 2).
Thymidine was tested as a positive control because it
is the normal substrate for viral and cellular TKs. In
C127I cells, thymidine triphosphate (TTP) levels were
slightly increased (1.4–1.7-fold) in TK+ virus-infected
cells compared with uninfected cells. The level of TTP
was depressed 46% in cells infected with the TK‑ virus.
This same pattern of triphosphate levels was seen in
IdU-treated C127I cells. IdUTP was enhanced 1.4-fold
by TK+ virus infection and depressed 64% by TK‑ virus
infection. In C127I cells treated with BrdU, similar
levels of BrdUTP were present in uninfected and TK+
virus-infected cells. BrdUTP was suppressed 65% in TK‑
virus-infected cells. The lower levels of nucleotide tri‑
phosphates in TK‑ virus-infected C127I cells compared
with uninfected cells might be due to host cell protein
shutdown (as a result of infection) that would interfere
with phosphorylating activity. This will require further
experimentation to support this hypothesis.
In LLC-MK2 cells, TTP, BrdUTP and IdUTP levels
were increased in TK+ virus-infected cells 3.1–4.6‑fold
compared with uninfected and TK‑ virus-infected
cells. The differences in TTP, BrdUTP or IdUTP levels
between uninfected and TK‑ virus-infected cells were

9

Virus yield, log10 PFU/ml

inhibiting the two TK+ viruses, indicating that the viral
enzyme did not enhance antiviral potency as it did for
BrdU and IdU in the LLC-MK2 cell infections. To fur‑
ther validate this pattern of antiviral activity seen with
(N)-MCT, we investigated its effects on vaccinia virus
yield (Figure 1). Virus yields were inhibited by much
lower concentrations of (N)-MCT in C127I cells than
in A549 and LLC-MK2 cells, confirming the plaque
reduction data in Table 1. From the results in the fig‑
ure, 90% (1 log10) and 99% (2 log10) inhibitory values
were calculated (Table 2). EC90 and EC99 values for the
TK‑ virus infections were within twofold of those of the
S‑Var virus and were similar to those of the WT virus.
The shapes of the dose–response curves were similar
for the three viruses in the three cell lines (Figure 1).
The combined results indicate that the viral TK does
not serve to markedly enhance the antiviral potency of
(N)-MCT in cell culture.
In untreated C127I cells, the S‑Var and S‑Var TK‑
viruses replicated to 100-fold lower titres than in the
other cell lines. WT virus replicated equally well in
untreated C127I and LLC-MK2 cells, and to about a
sixfold higher titre in A549 cells. These differences in
viral growth did not seem to have a large impact on
the antiviral potencies of (N)-MCT against the three
viruses in a particular cell line.

8
7
6
5
4
3
≤2
0

1

10
(N)-MCT, µM

Virus production in A549 cells
Virus production in C127I cells
Virus production in LLC-MK2 cells
(A) Wild-type virus, (B) S-variant (S-Var) virus and (C) thymidine-kinasedeficient (TK-) virus. Virus replicated 3 days in the presence of the compound,
then total virus yield was determined by plaque titration assays in Vero
cells. Data represent means ±sd for two independent assays. (N)-MCT,
N‑methanocarbathymidine; PFU, plaque-forming units; TK+, thymidinekinase-containing.
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Table 2. Antiviral activity of (N)-MCT in various cell lines against vaccinia (WR strain) TK+ and TK- viruses as determined by virus yield

Virus

C127I (mouse cells)
EC90*
EC99*

Wild-type
S-Var
TK-

1.0 ±0.8
0.4 ±0.1
0.8 ±0.7

Concentrations reducing virus yields in cells, µM
LLC-MK2 (monkey cells)
EC90*
EC99*

3.0 ±1.5
2.0 ±1.8
3.3 ±0.2

365 ±191
295 ±219
465 ±120

765 ±474
680 ±424
1,000 ±425

EC90 *

A549 (human cells)
EC99*

13 ±4.2
11 ±1.8
16 ±4.9

33 ±1.4
26 ±2.8
36 ±4.2

The wild-type and S-variant (S-Var) viruses contain thymidine kinase (TK+). The TK-deficient (TK-) virus was derived from the S-Var virus. *Concentration of
N‑methanocarbathymidine [(N)-MCT] that reduced virus yield by 90 or 99%. Viruses were propagated in the respective cell line, with virus yields determined in Vero cells.
Values are means ±sd for two independent assays.

Figure 2. Formation of metabolites of thymidine, BrdU and IdU in cells infected with TK+ (wild type and S-Var) and TK- strains of
vaccinia virus
Monophosphate
Diphosphate
Triphosphate
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(A) C127I and (B) LLC-MK2 cells. Treatment of the infection (5 mM compound) was for 12 h, followed by nucleotide analysis. Data represent means ±sd for two
independent assays. BrdU, 5‑bromo-2′-deoxyuridine; IdU, 5‑iodo-2′-deoxyuridine; S-Var, S-variant; TK+, thymidine-kinase-containing; TK-, thymidine-kinase-deficient;
uninf, uninfected; WT, wild type.
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Figure 3. Formation of metabolites of (N)-MCT in C127I and
LLC-MK2 cells infected with TK+ (wild type and S-Var) and TKstrains of vaccinia virus

A
Amount present, picomoles/106 cells

minimal, with levels in TK‑ virus-infected cells being
100%, 97% and 87% of those found in uninfected
cells, respectively. Overall, thymidine was phosphor‑
ylated to higher levels than were the two analogues in
both cell lines. This was not surprising because thy‑
midine is the natural substrate for the enzyme. IdU
phosphorylation slightly exceeded (by 1.6-fold) that of
BrdU (Figure 2, note that the Y‑axis scales differ with
each figure). Higher triphosphate levels were found in
uninfected and TK+ virus-infected LLC-MK2 cells than
in comparable C127I cells.

Phosphorylation of (N)-MCT in C127I and LLC-MK2 cells
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Infected and uninfected cells were treated with 3H‑(N)MCT and incubated for 12 h, followed by HPLC analy‑
sis of intracellular nucleotides (Figure 3). Based upon
the antiviral studies reported in Table 1 and Figure 1,
the 5 µM concentration of (N)-MCT was expected to
be highly inhibitory to virus production in C127I cells,
but not in LLC-MK2 cells. The 100 µM concentration
of (N)-MCT was expected to exert a moderately inhibi‑
tory effect on virus replication in LLC-MK2 cells. Using
a 5 µM (N)-MCT treatment, infection with the two TK+
virus strains caused increases in (N)-MCT monophos‑
phate levels as compared with uninfected and TK‑ virusinfected cells, but more so in LLC-MK2 cells (10.7-fold)
than in C127I cells (4.2-fold; Figure 3). A similar effect
(7.3-fold increase) was observed in LLC-MK2 cells with
the 100 µM treatment. The increase in intracellular (N)MCT monophosphate by infection with the TK+ viruses
did not result in a corresponding increase in the amount
of (N)-MCT triphosphate in these cells, where only
2.4–2.8-fold increases in triphosphate levels were seen
with the 5 µM treatment and up to 1.5-fold increase
at 100 µM. These differences are minimal, considering
that the TK‑ virus infection resulted in similar triphos‑
phate levels to those found in both uninfected and TK+
virus-infected cells. Importantly, the increases in (N)MCT triphosphate levels in TK+ cells did not translate
into an increase in antiviral potency (Tables 1 and 2).
The phosphorylation results suggest that the cells poorly
converted (N)-MCT monophosphate to diphosphate,
even though the viral enzyme was able to phosphorylate
the compound to much higher monophosphate levels in
TK+ virus-infected cells.
The amounts of (N)-MCT triphosphate in C127I
cells were comparable to those in LLC-MK2 cells at the
5 µM concentration (Figure 3). The average amount of
triphosphate (mean value derived from a summation of
triphosphate present in uninfected and virus-infected
cells) was 0.33 picomoles in C127I cells compared with
0.36 picomoles in LLC-MK2 cells. In LLC-MK2 cells
exposed to 100 µM (N)-MCT, 12.7-fold more (N)MCT triphosphate was present than at the 5 µM con‑
centration (note that the Y‑axis scales differ between
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(A) LLC-MK2 cells treated with 100 mM N‑methanocarbathymidine ([N]-MCT). (B)
LLC-MK2 cells treated with 5 mM N‑MCT. (C) C127I cells treated with 5 mM N‑MCT.
Treatment of the infection was for 12 h followed by nucleotide analysis. Data
represent means ±sd for two independent assays. TK+, thymidine-kinase-containing;
TK-, thymidine-kinase-deficient; S-var, S-variant; uninf, uninfected; WT, wild type.
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the two figures). There was an approximately 14‑fold
difference in the amount of triphosphate between LLCMK2 cells (100 µM compound) versus C127I cells
(5 µM compound).
These data show that a much higher concentration of
intracellular (N)-MCT triphosphate must be present in
LLC-MK2 cells than in C127I cells to cause a comparable
degree of inhibition of vaccinia virus replication.

Phosphorylation of (N)-MCT in L929, MA‑104, Vero
and A549 cells
The high antiviral potency of (N)-MCT in C127I
mouse cells and low potency in LLC-MK2 monkey cells
is not unique to these two cell types. The same effect
was reported in L929 mouse cells and in other mon‑
key cell lines such as MA‑104 and Vero, where plaque
reduction 50% effective concentration values for the
compound against WT vaccinia virus (WR strain) were
0.8, >1,000 and 620 µM, respectively [9]. (N)-MCT
was active against WT virus in A549 cells at 29 µM
(Table 1). Treatment of these cell lines with 5 µM (N)MCT resulted in the following amounts of (N)-MCT
triphosphate at 12 h, comparing uninfected to WT
virus-infected (uninfected/WT virus-infected): 0.44/0.4,
0.17/0.2, 0.17/0.36, and 0.1/0.34 picomoles/106 cells
for L929, MA‑104, Vero, and A549 cells, respectively.
Thus, (N)-MCT inhibited vaccinia virus in L929 cells
at very low (<1 µM) concentrations, even though the
amount of (N)-MCT triphosphate in those cells at 5 µM
was only twofold greater than the level in MA‑104 cells,
where no antiviral activity at 1,000 µM occurs.

Discussion
FdU, CldU, BrdU and IdU were found to be inhibitory
to TK+ and TK‑ strains of vaccinia virus in cell culture.
The antiviral potencies of BrdU and IdU compared
favourably with results obtained against cowpox virus
in human foreskin fibroblasts (HFF cells) [7]. However,
the reported potency of FdU was much less against cow‑
pox virus than against vaccinia virus. FdU was cyto‑
toxic to actively replicating C127I and LLC-MK2 cells,
whereas the other three compounds were not toxic at
1,000 µM. Prichard et al. [7] indicated that FdU was
not toxic to HFF cells, although it was not clear whether
they performed their assays using actively dividing cells
as opposed to stationary monolayers. We previously
reported some toxicity by IdU in actively dividing C127I
cells [18], but we were unable to confirm those results
with multiple experiments using the current lot of cells.
Because of the minimal potency differences of FdU
against TK+ and TK‑ viruses, we conclude that the
viral TK enzyme did not contribute to metabolism of
the compound, and that phosphorylation by a cellular
enzyme was sufficient for both antiviral and cytotoxic
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effects. This is supported by the fact that the compound
exhibited no antiviral activity in A549 cells, even when
infected with TK+ virus. It appears that A549 cells lack
a necessary phosphorylating enzyme for FdU.
CldU, BrdU and IdU were much more potent in TK+
virus-infected LLC-MK2 cells than in TK‑ virus-infected
cells. Prichard et al. [7] demonstrated a higher degree
of antiviral potency of BrdU and IdU against TK+
cowpox virus compared with TK‑ virus in HFF cells.
Later they demonstrated that purified vaccinia virus
TK phosphorylated BrdU, IdU and other compounds
[8]. The phosphorylation studies we conducted using
vaccinia-virus-infected cells treated with thymidine,
BrdU and IdU confirmed that higher levels of nucleoside
triphosphate were produced in TK+ virus-infected LLCMK2 cells. Less of a viral TK stimulatory effect on
triphosphate levels was seen in C127I cells. The antiviral
potencies of BrdU and IdU in C127I cells infected with
TK+ viruses were similar to or greater than those in
LLC-MK2 cells, although at lower triphosphate levels in
the C127I cell line. Since higher levels of triphosphate
should equate to greater inhibition of virus, the reason
why the compounds should be more active in C127I
cells is unclear. The same effect was also detected with
(N)-MCT in C127I-infected cells (see below).
(N)-MCT was shown to be inhibitory to vaccinia
plaque formation and virus yields from cell culture, and
the potency of inhibition was highly cell-line-dependent,
as was first reported [9]. Potency was greatest in C127I
cells, less in A549 cells and least in LLC-MK2 cells, con‑
firming the published data. We saw greater potency of
inhibition of virus in A549 cells than was previously
reported, which may be attributable to using a differ‑
ent lot of cells. The virus yield reduction data were in
agreement with the plaque reduction results for the
three cell lines.
(N)-MCT phosphorylation studies were conducted
to better understand the cell line dependency effect that
greatly favoured antiviral potency in mouse cells. We
hypothesized that intracellular levels of (N)-MCT tri‑
phosphate should be much greater in C127I cells than
in monkey or human cells treated with an equal concen‑
tration of the inhibitor, and this would explain antiviral
potency differences in vitro. For example, the greater
potencies of ribavirin and cidofovir in mouse cells
compared with monkey cells were due to greater phos‑
phorylation ([10] and unpublished data). Our hypoth‑
esis proved to be incorrect because similar amounts
of (N)-MCT triphosphate were found in C127I and
LLC-MK2 cells when treated with (N)-MCT at 5 µM.
Similar amounts of triphosphate were also found in
L929, MA‑104 and Vero cells, yet (N)-MCT was con‑
siderably more potent in L929 cells. The reason why
(N)-MCT should be considerably more active in C127I
and L929 cells than in the other cell lines is unclear.
© 2008 International Medical Press
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Viral replication efficiency in mouse cells is less than
in the monkey cell lines, perhaps making them more
sensitive to antiviral therapy. Considerable effort may
be required to study viral replication kinetics to under‑
stand why (N)-MCT is more efficient as an antiviral
agent in mouse cells than in monkey cells.
The purified vaccinia virus TK is able to phosphorylate
(N)-MCT to its monophosphate form (Mark Prichard,
University of Alabama at Birmingham, personal com‑
munication). Infection of cells with TK+ virus led to
increases in (N)-MCT monophosphate levels in C127I
and LLC-MK2 cells, but this did not translate into com‑
parable increases in intracellular triphosphate levels.
The data suggest that the monophosphate is converted
poorly to the diphosphate, thus inhibiting the conver‑
sion to triphosphate. Because of this effect, the viral
TK is not able to contribute to an enhancement of the
potency of (N)-MCT in cell culture, as measured by
plaque and virus yield reduction assays.
This article did not address the ability of triphosphate
forms of each compound to interact with the viral DNA
polymerase complex and possibly be incorporated
into viral DNA, thus stopping viral DNA replication.
This was beyond the scope of the project and would
require considerably more research effort. The data for
BrdU and IdU in LLC-MK2 cells suggest that the dose–
response curve for inhibition of viral DNA synthesis is
steep. This is based upon the observation that increase
in triphosphate in TK+ virus-infected cells compared
with TK‑ virus-infected cells was moderate (Figure 3),
whereas the realized gain in antiviral potency was much
greater (Table 1). For example, the difference in the
antiviral potency of IdU against the S‑Var (TK+) and
TK‑ viruses was 26‑fold, yet the difference in IdUTP
in cells infected with these viruses was only 4.6-fold.
Apparently, the amount of IdUTP in cells infected with
the S‑Var (and WT) viruses reached a threshold to cause
profound inhibition of viral replication. (N)-MCT tri‑
phosphate must be an extremely potent inhibitor of
viral DNA synthesis, because only very small quantities
of it were found intracellularly.
As was discussed previously [9], we do not believe
that (N)-MCT monophosphate exhibits antivaccinia
virus activity. There are several reasons for this posi‑
tion. First, nucleoside monophosphates are not known
to directly inhibit viral DNA polymerases. The nucleo‑
side monophosphates that are antivirally active do so by
inhibiting cellular enzymes. For example, the inhibition
of cellular thymidylate synthetase results in antipox‑
virus activity [19]. Inhibition of cellular thymidylate
synthetase also causes cytotoxicity. Because (N)‑MCT
is not cytotoxic at 1,000 µM, this suggests no inhibi‑
tory effect on this cellular enzyme. In addition, the
data in Figure 3 indicate an enhancement of (N)-MCT
monophosphate in TK+ virus-infected cells, without any
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enhancement in antiviral potency. Thus, the presence of
additional (N)-MCT monophosphate inside the cells is
inconsequential to virus inhibition.
The TK‑ virus that was used for these studies has not
been, to our knowledge, genetically characterized. It is
clear that the virus displays the correct phenotype as
a drug-resistant virus, particularly in LLC-MK2 cells
treated with BrdU and IdU. It also displays the correct
phenotype with regard to the lack of stimulation of
phosphorylation of thymidine, BrdU and IdU in cells
infected with the virus. Because the principal substrate,
thymidine, was not stimulated in its conversion to
nucleotides in infected cells (Figure 2), this suggests that
the enzyme is non-functional rather than merely being
altered in terms of substrate specificity. Because the virus
was propagated in cells treated with BrdU, the possibil‑
ity exists that it contains an altered DNA polymerase
that is less sensitive to inhibition by the compounds. As
was discussed previously [9], this seems unlikely based
upon the fact that the TK‑ virus and WT viruses were
nearly equally sensitive to BrdU in C127I cells as well
as were the other 5‑halogenated 2′-deoxyuridines and
(N)-MCT (as presented in this report).
It is concluded from these studies that in certain cell
lines the vaccinia virus TK plays a role in increasing the
phosphorylation of these analogues ([N]-MCT, CldU,
BrdU and IdU) of thymidine to their respective mono‑
phosphate form. This may lead to increased antiviral
potency, as was exemplified by the activities of CldU,
BrdU and IdU in LLC-MK2 cells. However, in other cell
lines such as C127I and L929, the presence or absence
of the viral TK does not appreciably affect the potencies
of these compounds. Because of the poor conversion of
(N)-MCT monophosphate to diphosphate in cells, viral
TK does not contribute to increased antiviral potency of
this compound. The differences in metabolism of BrdU,
IdU and (N)-MCT in uninfected, TK+ virus-infected and
TK‑ virus-infected cells could not explain why these com‑
pounds are more active in mouse cells than in monkey
cells, because nucleoside triphosphate levels were nearly
equal to or even higher in LLC-MK2 monkey cells. In the
case of (N)-MCT, its antiviral potency in mouse cells, as
determined by plaque reduction assay, was 100–1,000fold greater than in monkey cells [9]. This difference
might be related to less robust replication of the virus in
the mouse cells.
Cellular TK was presumably the enzyme responsible
for phosphorylation of BrdU and IdU in uninfected
cells, based upon the action of this enzyme in other cell
lines [20]. Cellular TK may also have phosphorylated
(N)-MCT, although no definitive metabolism studies
have been published with this compound and cellular
enzymes. In the cell lines used in the research, viral TK
made an additional contribution toward enhancing
phosphorylation and increasing antiviral potency
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of the 2′‑deoxyuridines. Other investigators have
indicated that poxvirus TK is responsible for activation
(monophosphorylation)
of
certain
nucleoside
analogues related to thymidine [7,8]. Some of those
compounds were highly dependent upon viral TK for
antiviral activity, suggesting that phosphorylation
by cell TK was minimally contributory. This effect
confers a great degree of selectivity to the antiviral
agent. The results presented here indicate that the
particular cell line in which the virus infects influences
how much of the compound reaches the triphosphate
form. Thus, one could surmise that the antiviral
efficacies of these types of selective compounds might
be effected (either favourably or negatively) based
upon the particular cells in which the viral infection
was taking place. When considering the treatment
of animals or humans, this might depend upon the
animal species or even within the same species where
there are innumerable cell types. It will be important
to evaluate these newer antipoxvirus compounds
in a variety of cells from various animal species to
determine how cell-line-dependent they are.
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